POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells

09.12.2022

Mutations in breast cancer susceptibility proteins 1 and 2 (BRCA1/2) are the most common genetic predisposition associated with familial breast and ovarian cancer. Thus, there is a growing interest in identifying synthetic lethal interactions of BRCA1/2 that can be exploited for targeted therapy, exemplified by the exquisite hypersensitivity of BRCA1/2-deficient cells to inhibitors of poly(ADP-ribose) polymerases (PARPs).

Anna Schrempf, Sara Bernardo, Emili A. Arasa Verge, Miguel A. Ramirez Otero, Jordan Wilson, Dominik Kirchhofer, Gerald Timelthaler, Anna M. Ambros, Atilla Kaya, Marcus Wieder, Gerhard F. Ecker, Georg E. Winter, Vincenzo Costanzo, Joanna I. Loizou, POLθ processes ssDNA gaps and promotes replication fork progression in BRCA1-deficient cells, Cell Reports, Volume 41, Issue 9, 2022.

DOI

https://doi.org/10.1016/j.celrep.2022.111716

Abstract

Polymerase theta (POLθ) is an error-prone DNA polymerase whose loss is synthetically lethal in cancer cells bearing breast cancer susceptibility proteins 1 and 2 (BRCA1/2) mutations. To investigate the basis of this genetic interaction, we utilized a small-molecule inhibitor targeting the POLθ polymerase domain. We found that POLθ processes single-stranded DNA (ssDNA) gaps that emerge in the absence of BRCA1, thus promoting unperturbed replication fork progression and survival of BRCA1 mutant cells. A genome-scale CRISPR-Cas9 knockout screen uncovered suppressors of the functional interaction between POLθ and BRCA1, including NBN, a component of the MRN complex, and cell-cycle regulators such as CDK6. While the MRN complex nucleolytically processes ssDNA gaps, CDK6 promotes cell-cycle progression, thereby exacerbating replication stress, a feature of BRCA1-deficient cells that lack POLθ activity. Thus, ssDNA gap formation, modulated by cell-cycle regulators and MRN complex activity, underlies the synthetic lethality between POLθ and BRCA1, an important insight for clinical trials with POLθ inhibitors.

Rights & permissions

Open Access This is an open access article distributed under the terms of the Creative Commons CC-BY license, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Graphical abstract

 More News

Project
 

InSilify DrugTox is amongst the seven projects that were granted by the Austrian Science Fund FWF to enable research on different possibilities to...

News
 

We warmly welcome Sharath to the Pharminfo group! His expertise includes AI-assisted drug discovery and cheminformatics. We look forward to working...

Project
 

We are excited that our project AI4Health - Using AI for detecting drug-drug interactions - was recently granted by the Vienna Business Agency.